Result of PI-88’s interim analysis

Independent Data Review Board conducted interim analysis for PI-88 on July 27th, 2014 with the following discoveries:
A. PI-88 poses no safety concerns.
B. The primary endpoint, Disease Free Survival (DFS) has not met its expected efficacy based on data gathered.
All the data will be aggregated for further centralized analysis by a Pennsylvania-based company, BioClinica.